NASDAQ$CERS

Cerus Corp · Q2 2020 earnings

Q2 2020 earnings · · Investor relations

Briefing

Cerus's Q2 2020 results were announced, featuring record quarterly product revenue and progress in development programs.

Cerus Corporation announced record second-quarter results, with total revenue reaching $26.8 million. Product revenue was $21.5 million, driven by strong platelet kit sales in the U.S. and plasma and illuminator sales in EMEA. The company reaffirmed its full-year product revenue guidance of $89 million to $93 million.

  • Total revenue reached $26.8 million, a 19.1% increase year-over-year.
  • Product revenue hit a record $21.5 million, driven by platelet kit sales in the U.S. and plasma and illuminator sales in EMEA.
  • Reaffirmed 2020 full-year product revenue guidance of $89 million to $93 million.
  • Submitted a pre-market approval supplement to the FDA for pathogen-reduced cryoprecipitated fibrinogen complex.

Headline financials

Total Revenue

$21.5M

Previous: $18.2M+18.1%
EPS (adj)

-$0.09

Previous: -$0.13+30.8%
Product Gross Margin

55.0%

No prior period
Net Income

-$14.9M

Previous: -$17.6M+15.3%
Operating Income

-$14.6M

Previous: -$16.8M+13.0%
Cash & Equivalents

$34.9M

Previous: $23.5M+48.2%

Revenue & EPS history

Cerus · Revenue · Quarterly

$21.5M

Q2 2020+18.1%vs Q2 2019
Beat estimate in 2 of 16 quarters(13%)
ActualEstimate

Revenue by segment

Cerus · $26.8M total across 2 segments · Q2 2020

  • Product Revenue
    $21.5M+18.1%
  • Government Contract Revenue
    $5.3M+23.3%

Forward guidance

The Company expects 2020 product revenue to be in the range of $89 million to $93 million, unchanged from the guidance originally provided on January 13, 2020. The guidance range represents approximately 20% to 25% growth compared to 2019 reported product revenue.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2020

Historical avgQ2 2020

-0.4%

Avg return

Earnings day

+1.0%

Avg return

5 days after

-0.8%

Avg return

30 days after

48%

31 / 65 earnings

Positive

+27.5%

Q3 2017

Best reaction

-19.6%

Q1 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+5.7%+34.9%+58.3%
Q4 2025-17.3%-23.7%-26.5%
Q3 2025-2.8%+0.0%+21.4%
Q2 2025+0.8%-2.3%+3.9%
Q1 2025+2.3%+0.0%-2.3%
Q4 2024-5.2%-5.7%-12.1%
Q3 2024-7.6%-8.2%+8.8%
Q1 2024-5.8%+7.6%+4.1%
Q4 2023+14.2%+6.6%-10.8%
Q3 2023+25.4%+25.4%+21.0%
Q2 2023-17.8%-26.3%-35.4%
Q1 2023-0.9%-6.1%-1.7%
Q4 2022-7.0%+2.1%-1.4%
Q3 2022+7.7%+6.0%+18.9%
Q2 2022-4.5%-12.7%-32.8%
Q1 2022+2.9%-2.7%-2.3%
Q4 2021-2.1%+8.6%+3.6%
Q3 2021+14.5%+16.0%+1.5%
Q2 2021+21.1%+21.9%+28.2%
Q1 2021+2.7%+4.8%-7.7%
Q4 2020-8.6%-3.9%-11.3%
Q3 2020-5.4%-0.4%+18.6%
Q2 2020-1.8%-4.7%-17.7%
Q1 2020+2.1%+5.2%+12.5%
Q4 2019-1.0%-6.0%-39.2%
Q3 2019-4.4%-3.7%-4.6%
Q2 2019-8.7%-13.5%-8.2%
Q1 2019-12.3%-15.2%-27.3%
Q4 2018+2.8%+6.5%-3.7%
Q3 2018-4.9%-13.4%-21.6%
Q2 2018-5.9%-4.8%+4.1%
Q1 2018+11.9%+17.1%+17.8%
Q4 2017+2.1%+7.5%+9.0%
Q3 2017+27.5%+26.4%+40.9%
Q2 2017+3.6%+7.1%+6.7%
Q1 2017-19.6%-28.3%-44.5%
Q4 2016-7.8%+5.0%+0.7%
Q3 2016+6.4%+15.0%+10.2%
Q2 2016+1.8%-4.5%-11.3%
Q1 2016-6.6%
Q4 2015+0.5%
Q3 2015+4.5%
Q2 2015-2.5%
Q1 2015+0.3%
Q4 2014-12.7%
Q3 2014-5.8%
Q2 2014+4.8%
Q1 2014+4.4%
Q4 2013-15.7%
Q3 2013-6.1%
Q2 2013+6.7%
Q1 2013-9.7%
Q4 2012+14.0%
Q3 2012-1.9%
Q2 2012-2.7%
Q1 2011+0.5%
Q1 2012+1.5%
Q4 2009+0.8%
Q4 2011+0.8%
Q3 2010+1.4%
Q3 2011+1.4%
Q2 2010-2.8%
Q2 2011-2.8%
Q4 2010-2.8%
Q1 2010-2.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro